Join to view full profile
8700 Beverly Blvd., A9102Los Angeles, CA 90048
Phone+1 310-423-1160
Dr. Merchant is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Akil Merchant is co-Director of the Lymphoma Program at Cedars-Sinai Medical Center in Los Angeles, CA. He did his fellowship in Medical Oncology at Johns Hopkins University and was on the faculty at LAC-USC and the USC Norris Cancer center. He specializes lymphoma treatment and cellular therapies including CART and bone marrow transplantation.
Clinical Expertise
- Bone marrow transplantation, Leukemia, Hematologic oncology, Myeloproliferative disease, Oropharyngeal lymphoma
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2005 - 2008
Baylor College of MedicineResidency, Internal Medicine, 2000 - 2005- Baylor College of MedicineClass of 2000
Certifications & Licensure
CA State Medical License 2012 - 2027
MD State Medical License 2005 - 2013
TX State Medical License 2002 - 2005
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2017
- CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2017
- CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2017
Clinical Trials
- Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Start of enrollment: 2013 Dec 24
- Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
- EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia Start of enrollment: 2018 May 09
Publications & Presentations
PubMed
- Fludarabine and Total Body Irradiation 800 or 1125 cGy for Allogeneic Stem Cell Transplant Using Graft-Versus-Host Disease Prophylaxis with Post-Transplant Cyclophosph...Ronald Paquette, Haein Kim, Vinicius F Calsavara, Noah Merin, John Chute
Transplantation and Cellular Therapy. 2026-09-07 - Mutational profiling of HIV+ diffuse large B-cell lymphoma reveals distinct mutational features with evidence of genomic instability.Sophia M Roush, Samantha Beck, Jenny Coelho, Amon Chirwa, Marriam Mponda
AIDS. 2026-06-01 - 1 citationsMultidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.Tomohiro Aoki, Gerben Duns, Shinya Rai, Aixiang Jiang, Andrew Lytle
Cancer Discovery. 2026-05-01
Abstracts/Posters
- Highly Multiplexed Single Cell Spatial Analysis of the Tumor Microenvironment in Lymphoma Predicts Clinical OutcomesAkil Merchant, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Single Cell Transcriptome Analysis Reveals Disease-Defining T Cell Subsets in the Tumor Microenvironment of Classic Hodgkin LymphomaAkil Merchant, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Researchers Identify Patterns That Predict Ovarian Cancer RelapseApril 18th, 2024- A Leading-Edge Lymphoma ProgramDecember 21st, 2022
- The More Pandemic Precautions Fall Away, the More COVID Risk Is Concentrated on This One GroupDecember 2nd, 2022
Grant Support
- Spatially resolved, single cell biomarkers of B cell lymphomaCEDARS-SINAI MEDICAL CENTER2022–2027
- Diversity and Determinants of the Immune-Inflammatory Response to SARS-CoV-2CEDARS-SINAI MEDICAL CENTER2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: